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ABSTRACT: Cyclic guanosine monophosphorothioate analogue 1a is currently showing potential as a drug for the treatment of
inherited retinal neurodegenerations. To support ongoing preclinical and clinical work, we have developed a diastereoselective
synthesis via cyclization and sulfurization of the nucleoside 5′-H-phosphonate monoester, which affords the desired RP-3′,5′-cyclic
phosphorothioate in 9:1 ratio to the undesired SP-diastereomer. This route was made viable as a result of the silyl protection
sequence used, which achieved >80% selectivity for 2′,5′-hydroxyls over 3′,5′-hydroxyls. Finally, the chromatography-free process
allowed for a scale-up, as intermediates and the final product were isolated by crystallization to give 125 g of 1a (13.8% total yield)
with over 99.9% HPLC purity.
KEYWORDS: cyclic guanosine monophosphate, cyclic guanosine monophosphorothioate, nucleotide H-phosphonate,
retinal neurodegenerations, process development, preclinical development
■ INTRODUCTION
Recent research suggests that photoreceptor death in inherited
retinal neurodegenerations (IRDs) is predominantly governed
by a nonapoptotic pathway, which is partly mediated by
overactivation of cGMP-dependent protein kinases (PKG).1
This overactivation stems from an unnatural build-up of 3′,5′-
cyclic guanosine monophosphate (cGMP) in photoreceptors
caused by disruptions of the phototransduction cascade.2 A
great number of cGMP analogues were therefore investigated
for their affinity to block PKG and thus potentially act as
therapeutic agents for IRDs.3 The result was the discovery of a
promising cyclic guanosine monophosphorothioate (cGMPS)
analogue, 1a, with potent neuroprotective effects in vivo.4
The compound is an 8-bromo-cGMPS derivative with a
phenylethenyl (PET) group on the nucleobase and an RP-
configuration on the thiophosphate. Cyclic nucleotide mono-
phosphorothioates (cNMPSs) are known to resist cleavage by
phosphodiesterases and therefore survive longer in cells than
their phosphate counterparts, which adds to the potential of 1a
as a therapeutic agent. In contrast to the antagonistic activity
toward PKG of analogue 1a, its SP-diastereomer 1b and the
phosphate equivalent 1c were both found to be PKG agonists
similarly to natural cGMP5,6 (Figure 1).
For further the preclinical development, a scalable and
robust synthetic process for the preparation of highly pure 1a
was needed. The present report describes our work with the
development of suitable chemistry to achieve this.
Published cyclic phosphorothioate syntheses include those
by Stec et al.,7 involving reactions of phosphorylchlorides with
aniline to obtain a mixture of phosphoroanilidate diaster-
eomers, which are then separated. The desired isomer is
treated with a strong base and carbon disulfide (the Stec
reaction) to yield the cyclic thiophosphate with complete
retention of configuration. Eckstein and Kutzke used
bisnitrophenyl phosphorochloridothioate on unprotected
nucleosides to prepare 5′-bisnitrophenyl phosphorothioates.
These were directly cyclized by treatment with potassium tert-
butoxide.8 Genieser’s group used a similar approach by
employing thiophosphorylchloride to obtain 5′-thiophosphor-
odichloridates as precursors for the cyclization step and was in
fact the first group to synthesize 1a as described in their
patent.3 In all the abovementioned cases, cNMPSs (or their
precursors) were obtained as diastereomer mixtures and later
separated by chromatography. In a more recent synthesis,9
Andrei et al. took inspiration from these methods and
developed a stereoselective chlorination−amidation−Stec
sequence, this time with cyclic adenosinemonophosphate as
the starting material. However, only the RP-diastereomer was
available with this tactic, and further chromatographic
purification was still required.
An entirely different approach toward cGMPSs is the H-
phosphonate route developed by Kraszewski and co-workers.10
It entails the internal cyclization of a nucleoside-3′-H-
phosphonate monoester with the help of a coupling agent to
form the corresponding 3′,5′-cyclic H-phosphonate diester,
followed by sulfurization to afford the cyclic thiophosphate. In
their report, it was shown that 3′,5′-cyclic nucleoside H-
phosphonates were formed in a diastereoselective manner and
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that this selectivity can be directed toward the diastereomer of
preference.
■ RESULTS AND DISCUSSION
Route Development. We found the H-phosphonate
approach to be most promising, and thus, it became the
focus of our development. We noted that in the reported
synthesis of 1a by Genieser et al.,3 the 1,N2-phenylethenyl
(PET) group is introduced after formation of the cyclic
phosphorothioate. Also, it was performed without any
protection on the 2′-hydroxyl. A corresponding H-phospho-
nate approach would be more susceptible to side reactions on
the nucleobase and ribose. Therefore, our synthetic design
aimed to introduce the PET group first, as it should function
analogously to a protecting group, and a protecting group at 2′
in order to negate the formation of 2′,3′-cyclic side products.
Importance was placed on avoiding chromatographic purifica-
tions in favor of crystallizations and on the process’ ability to
control the level of key impurities such as the undesired PKG
agonists 1b and 1c; however, at this early stage, no
identification of other side products or mass balance analyses
were performed. Finally, the work toward selection of
appropriate API salts and solid forms is ongoing, and we
describe a process toward the triethylammonium salt of 1a
(summarized in Scheme 1), as it was found that it could be
readily crystallized.
Phenylethenylation. The reported synthesis of an 8-
bromoguanosine with a 1,N2-phenylethenyl (PET) modifica-
tion used a 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)−
DMSO combination, and it served as a starting point for our
development.3 Dissolving 8-bromoguanosine in 10 volumes
(mL/g) of DMSO and adding 5 equiv of 2-bromoacetophe-
none followed by 7 equiv of DBU caused consumption of the
starting material within 30 min, with the formation of 8-
bromoPETguanosine 2 as the major product (∼70% LC area).
We found that reducing the amounts of 2-bromoacetophenone
and DBU to 1.5 and 2.5 equiv, respectively, did not
compromise conversion. Overall, the reaction seemed to be
robust, as little variation in product formation was seen when
varying stoichiometry. After quenching the excess base with 3
equiv of acetic acid, addition of water (15 volumes)
precipitated the product as a slightly colored solid.
In our attempts to improve the volume efficiency, adding the
base before the bromoketone was investigated.11 8-Bromogua-
nosine could then be dissolved in only 4 volumes of DMSO,
but this addition order reduced yields to around 50%, and the
approach was discarded. It was later noticed that dried 8-
bromoguanosine has improved solubility in DMSO. The
commercial 8-bromoguanosine was found to contain ∼8%
water (Karl Fischer) and required at least 8 volumes of DMSO
for dissolution. The water content could be reduced to <0.5%
by vacuum drying at temperatures up to 80 °C without
Figure 1. Target cGMPS 1a, cGMP, and some key potential impurities.
Scheme 1. Synthetic Route to 1a as a Triethylammonium Salt by the H-Phosphonate Methoda
a(i) 2-Bromoacetophenone, DBU, and DMSO; (ii) triisopropylsilyl chloride, imidazole, and DMF; (iii) TFA, H2O, and THF; (iv) DPP, pyridine/
DCM → H2O, and Et3N; (v) PvCl, 2,6-lutidine, DCM → S(s), and Et3N; and (vi) Et3N·3HF, and THF.
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affecting purity, and the dried material gave clear solutions in 5
volumes of DMSO within 15 min.
Regarding precipitation of the product, no improvement in
purity or yields was observed when more than 4 volumes of
water was added to the resulting reaction mixture. Rapid water
addition should be avoided, as it caused formation of sticky
lumps. It was also noted that not neutralizing the reaction
mixture with acetic acid beforehand caused the same effect,
even with slow addition of water. A final cake wash using
MeCN removed the colored impurities. Thus, performing the
reaction in 5 volumes of DMSO and precipitating the product
using 4 volumes of water, followed by a wash with MeCN,
yielded intermediate 2 as a white solid in 71% yield. The
product was found to be crystalline and >99% pure (HPLC).
Protection Strategy. Introducing a protecting group at
the 2′-position can usually not be achieved without also
introducing one at 5′, which then needs to be removed.
Additionally, achieving selectivity for the 2′-hydroxyl over the
3′-one is still a challenge.12 Usually, this is addressed by
separation of isomers via chromatography, which we aim to
avoid. It is possible to bypass this competition with the help of
silylating agents that simultaneously block the 5′- and 3′-
positions, which can be removed after further protection of the
2′-position,13,14 for instance with 1,3-dihalo-1,1,3,3-tetraalkyl-
disiloxanes. Although this is a popular approach, it generally
involves an extra step for the 2′-protection, and better success
was obtained by optimizing the traditional silylation for
selectivity toward this position and developing a selective
crystallization, as described below.
Selective Protection. Initially, t-butyldimethylsilyl chlor-
ide (TBDMS-Cl), commonly used as a protecting group for
nucleosides, was evaluated.15,16 When using 2.5 equiv of
TBDMS-Cl and 5 equiv of imidazole in DMF, the 5′-
monosilylated intermediate was formed and consumed within
1.5 h, but no selectivity toward any of the secondary hydroxyls
was seen. Furthermore, the 2′,3′,5′-trisilylated side product
constituted 44% of the product composition.
Next, triisopropylsilyl chloride (TIPS-Cl) was evaluated, as
it has been reported to give increased selectivity for the 2′-
positions over the 3′-positions in guanosine analogues and be a
more stable silyl protection group when compared to TBDMS-
Cl.17,18 When TBDMS-Cl was replaced with TIPS-Cl, less than
1% trisubstitution was seen after three days, while formation of
the disilyl species occurred with initial 85:15 ratio, favoring the
2′,5′-ditriisopropylsilyloxy nucleoside over the unwanted 3′,5′-
isomer (Table 1, entry 1). However, a 2′ → 3′ silyl migration
does occur over time, and the isomers generally approached
60:40 ratio over several days. Unfortunately, protection of the
second hydroxyl position was slow enough to allow the mixture
to undergo some isomerization before complete consumption
of the 5′-monosilyloxy nucleoside. In one trial using 130 g of
the starting material, when only 1.5% of the intermediate
remained after two days, the disilylated products had 70:30
isomer ratio.
Following an extractive work-up and evaporation, the
resulting oil was subjected to crystallization studies. It was
found that crystallization could be induced from several
solvents, although several days could be required for complete
desaturation. MeOH was found to selectively crystallize the
undesired 3′,5′-isomer, while other solvents were selective for
the 2′,5′-isomer. In the latter case, only the excess of the 2′,5′-
disilyl crystallized, leaving a nearly 1:1 isomer mixture in the
mother liquor. For instance, isopropyl acetate gave >98% pure
crystalline material in 33% isolated yield. Encouraged by this,
attempts were made to improve on the product loss to filtrates.
All the attempts to increase crystallization yields by changing
solvent volumes and addition of antisolvents were unfruitful as
an increase in yield was always at the expense of purity. Next, a
two-step crystallization was attempted, first removing some of
the undesired isomer with a crystallization from MeOH and,
after evaporation, recrystallizing the mother liquor residue
from isopropyl acetate. This gave the product in a somewhat
improved yield of 40%. Still, this two-step operation was time-
consuming and therefore not adopted on scale. A few attempts
to find dynamic conditions (addition of DBU and TEA) where
the 3′,5′-isomer would isomerize to the desired 2′,5′ during
the crystallization failed. Either no isomerization or no
crystallization occurred. The conclusion from the crystalliza-
tion studies was that to increase the isolated yield of 3, the
regioselectivity of the silylation had to be improved. It proved
to be a challenge to increase the silylation rate without equally
increasing 2′ → 3′ silyl migration rates. Attempts included
other solvents (pyridine and NMP), using various bases, and
increasing reaction temperatures. Side product formation and
increased isomerization were observed on the latter, and while
some conditions were found which improved isomer ratios at
full conversion (Table 1, entry 3); the most notable result
came from using 5 equiv of both imidazole and TIPS-Cl
(Table 1, entry 4). This encouraged the second silylation step
to complete after one night, while the isomer remained at
86:14. When these conditions were used on a larger scale, the
reaction mixture contained 1.7% of the 5′-monosilyl
intermediate and 77:23 ratio between the disilylated products
after one night. Finally, crystallization gave 3 in 58% yield and
>98% purity.
Having this step as the first in the synthesis was also
explored, since it gave the lowest yields. However, crystal-
lization of the resulting crude was unsuccessful, and
chromatography was needed for isolation. Moreover, the
strongly basic conditions for the subsequent PET step also
Table 1. Effect of Reaction Conditions on the Disilylation
Rate in Terms of the Monosilyl Intermediate Consumed










1 2.5 5 2 h 85 85:15
overnight 20 75:25
2 nights 9 68:32
2b 2.5 5 2 h 50 69:31
overnight 11 61:39
3 2.5 10 2 h 85 83:17
overnight 27 66:34
4 5 5 2 h 66 86:14
overnight 5 86:14
5 2.5 2.5 2 h 89 84:16
overnight 44 81:19
6 2.5 5c 2 h 14 69:31
overnight 9 69:31
7 2.5 5d 2 h 66 70:30
overnight 34 69:31
aUnless otherwise stated, the base was imidazole. bReaction was run
at 90 °C. Side product formation was observed. cDBU was used as
base. dEt3N was used as base.
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caused some silyl migration, and we did not pursue this
sequence further.
Selective Deprotection. We first investigated AcOH in
H2O and TFA/H2O in THF, as these are reported to
preferentially hydrolyze the 5′-silyl.15,19 The starting material
was insoluble in the first mixture, while the latter was found to
give good results under mild conditions. Still, the effects of
solvents, acid strength, concentrations, and water content on
the ratio of product 4 to overhydrolyzed side product 2 (see
Table 2) were explored.
In general, a 10:0.5:2 vol combination of solvent/TFA/
water was convenient, as conversion occurred overnight with
minimal overhydrolyzation. More concentrated mixtures or
stronger acids such as HCl gave more hydrolysis of the
secondary silyl ether. Using MeOH, either neat (Table 2, entry
9) or in combination with water (Table 2, entries 7 and 8),
significantly slowed conversions. Toluene and DCM gave
similar reaction rates when compared to THF, but the former
was not able to dissolve the starting material well. DCM
(Table 2, entry 5) was favored over THF (Table 2, entry 1), as
it also precipitated 2 continuously, but the heterogeneous
conditions could give more analytical inconsistencies.
After quenching with aqueous ammonia and a filtration to
remove 2, the organic phase was washed with water and
evaporated. After reslurrying the concentrate in MeCN, the 2′-
monosilyloxy nucleoside 4 was recovered in 74% yield and
>99% purity as a crystalline solid.
H-Phosphonate Monoester Formation. Diphenyl phos-
phite (DPP, diphenyl H-phosphonate) is a common reagent
for the formation of nucleoside H-phosphonate monoesters.20
It readily undergoes transesterification with alcohols and
nucleosides in pyridine, forming mixed phenyl H-phosphonate
diesters (e.g., diester 7, Scheme 2). After hydrolysis of the
phenyl moiety, a nucleoside monoester is obtained in good
yield. When DPP (1 equiv to reduce the risk of bisester
formation since 4 has two free hydroxyls) was added to a
solution of 4 in pyridine, several peaks appeared on 31P NMR,
resonating between 0 and 15 ppm. These likely correspond to
formation of the 3′,5′-cyclic H-phosphonate, 3′-mixed ester, or
dinucleoside ester in addition to the desired intermediate 7,
but no attempts to assign the peaks were made. As the system
seemed too reactive, a less-basic solvent mixture containing 5%
pyridine in DCM was evaluated. Using this system, a clean
formation of mixed ester 7 was seen on 31P NMR, but
conversion rates were slow. When the amount of DPP was
increased to 3 equiv, full conversion occurred within 1 h and
without the side products observed with neat pyridine.
Addition of water and triethylamine after 1 h hydrolyzed the
mixed ester 7 and afforded the triethylammonium 5′-H-
phosphonate monoester 5. Extractive work-up removed most
of the residues from the hydrolyzed DPP from the organic
phase. Evaporation gave a crude from which monoester 5 was
found to crystallize in 90% yield and >96% purity when using
EtOAc.
An alternative sequence was also briefly explored (Scheme
3). Disilyl intermediate 3 could also be phosphonylated at the
3′-OH, yielding monoester 8. Acidic deprotection of the 5′-
silyl group gave the 2′-protected-3′-H-phosphonate monoester
9. Although promising, this sequence was not pursued further,
as crystallization attempts of intermediates 8 and 9 as their
triethylammonium salts were unsuccessful.
H-Phosphonate Cyclization. In the reported method, a
mixture of 19:1 DCM/Pyridine was used, with pivaloyl
chloride (Pv-Cl) as a coupling agent.10 Using these conditions,
the first NMR spectrum recorded (after ca. 10 min) showed
7:3 ratio between two peaks at 0.1 ppm (1JPH = 734 Hz) and
5.8 ppm (1JPH = 704 Hz), which is in accordance with the
formation of the SP/RP-cyclic H-phosphonates.
10 Treatment of
this mixture with elemental sulfur after 20 min yielded the
corresponding 7:3 RP/SP cyclic phosphorothioate mixture
(retention of configuration;21 56.4 and 55.1 ppm, 3JPH = 18
and 24 Hz, respectively). The isomerization between the cyclic
H-phosphonate diastereomers described by Kraszewski and co-
workers was also observed: allowing a ring closure to stand
Table 2. Effect of Reaction Conditions on Conversion of
2′,5′-Disilylated Nucleoside 3 to 2′-Monosilylated






TFA/H2O time 3 4 2
1 THF 0.5/2 1 h 49 51 <1
overnight <1 92 8
2 0.5/1 1 h 60 40 <1
overnight 1 93 6
3 0.5/0 1 h 97 3 <1
overnight 92 8 <1
4 0.1/2 1 h 81 19 <1
overnight 25 73 2
5 DCMa 0.5/2 1 h 43 57 <1
overnight <1 98 2
6 toluenea 0.5/2 1 h 25 73 2
overnight <1 98 2
7 MeOH 0.5/2 1 h 89 11 <1
overnight 32 63 4
8 0.5/1 1 h 92 7 1
overnight 37 59 4
9 0.5/0 1 h 98 2 <1
overnight 69 30 1
aHeterogeneous systems may have led to misrepresentative analytical
readings.
Scheme 2. Formation of H-Phosphonate Monoester 5
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overnight in neat pyridine yielded the cyclic H-phosphonates
in 1:9 SP/RP ratio (which would yield the sulfurized products
in undesired 1:9 RP/SP ratio), showing that the initially formed
cyclic SP-H-phosphonate is the kinetic product and that
equilibrium favors the undesired diastereomer (Scheme 4).
To preserve the desired kinetic product, 2,6-lutidine was
explored, as it has been shown to reduce the rate of
epimerization in comparison to pyridine.22 When performing
the reaction in DCM with 5 equiv of 2,6-lutidine, our NMR
experiments showed the cyclic H-phosphonate diastereomers
in an initial 19:1 SP/RP ratio and 13:1 at 30 min.
23
Another commonly used coupling agent, diphenylchlor-
ophosphate (DPCP), was also tried, but it gave the same
diastereomer ratios and offered no benefits. On smaller scales,
1.2 equiv of the coupling agent tended to become quenched
from repeated exposure to the environment during sampling.
In these cases, 1.5 equiv of Pv-Cl ensured full conversion and
tolerance to adventitious water. A larger excess of the coupling
agent should be avoided, as some side products became more
pronounced, particularly DPCP. A total of 1.5 equiv of Pv-Cl
was chosen for up-scaling, both for consistency and due to
similar concerns regarding exposure from handling on larger
scales.
When sulfurizing the cyclic H-phosphonates, a 50% excess of
sulfur and Et3N was found sufficient. No other sulfurizing
agents besides elemental sulfur were evaluated. Suitable
sulfurization timings were determined by adding reaction
aliquots to vials containing sulfur and Et3N at different times
after addition of Pv-Cl. Charging of sulfur before 45 min left
unreacted intermediates, and longer times were associated with
degrading diastereomeric ratios. However, after addition of
sulfur/Et3N, the reaction mixtures were stable over several
nights. Usually, the final sulfurized mixture contained 75−80%
of the desired product (according to 31P NMR), the remainder
being the undesired diastereomer and small amounts of the
starting material and impurities in the phosphite area (>110
ppm) and product area (∼50 ppm).
After extractive work-up and a solvent swap to MeCN to
precipitate residual sulfur, filtration and evaporation gave the
crude product as a viscous oil. Despite several solvent screens,
crystallization of the product as a triethylammonium salt from
this crude was unsuccessful, although we were able to force
precipitation by addition of 1 M HBr(aq) as an impure and
amorphous solid, which was easier to handle. During the final
up-scaling, 31P NMR and LC showed that the crude product
contained the protected API 6 in approximately 9:1 ratio to the
SP-diastereomer.
Deprotection of 2′-Protected API. Initial deprotection
screens using Et3N·3HF in MeCN, THF, dioxane, and EtOH
as solvents proved immediately fruitful. The 2′-silyl was
removed with no observable side reactions, and we were
delighted to find that the target cGMPS 1a spontaneously
precipitated out over the course of three days, and the mother
liquor was enriched with the undesired diastereomer and the
other impurities. THF was the solvent of choice because it
gave the lowest losses to the mother liquor. The crude product
was a slightly yellow crystalline salt that was almost pure on
LC. However, its 1H spectrum revealed the presence of two
equivalents of triethylammonium cation, despite vacuum
drying. 19F NMR showed a broad peak around −162 ppm,
indicating the presence of a fluoride complex, presumably
triethylammonium fluoride. A reslurry in MeCN removed the
fluoride, excess Et3N, and all color, yielding the product in a
crude form containing ∼1% of the undesired diastereomer.
After a small solvent screen, ethanol was found to be a suitable
recrystallization solvent, from which the product was recovered
as a crystalline hemi-ethanol solvate. This solvate was stable
and remained intact despite vacuum drying, and calorimetry
Scheme 3. Alternate Sequence via Disilylated 3′-H-Phosphonate Monoester 8
Scheme 4. Formation of Nucleoside Cyclic H-Phosphonates which Undergo Epimerizationa
aSulfurization occurs with retention of configuration and stops the isomerization.
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analyses showed no endotherms or loss of sample mass when
heating. The crude product was found to be soluble in 20
volumes of boiling EtOH with no evident degradation, which
made it possible to perform a cooling recrystallization. This
afforded the target compound as a crystalline white powder in
49.5% yield (two steps) with >99.9% LC purity. Confirmation
of the correct structure and conformation came from
comparison of its spectroscopic data with those of the material
previously prepared by the partner organization BIOLOG Life
Science Institute (Bremen, Germany).
■ CONCLUSIONS
A six-step batch process for preparation of cGMPS 1a without
chromatography or chiral auxiliaries was developed and
upscaled. Use of the H-phosphonate approach allowed us to
form the desired RP-cyclic phosphorothioate in 9:1 ratio to the
undesired SP-diastereomer. To make this route viable, a 2′-silyl
protection strategy was selected and optimized to give the
desired 2′,5′-disilylated nucleoside in 86:14 ratio to the 3′,5′-
isomer. Although isolation of the 2′-protected cGMPS 6 was
not achieved, selective crystallizations were possible for all
other steps. The process afforded a total of 126 g of >99.9%
pure, crystalline 1a (13.8% total yield), which has allowed the
next stage of its pharmaceutical development to begin,
including studies of its salts, solid states, and formulations.
■ EXPERIMENTAL SECTION
General Information. All reagents and solvents used in
chemical synthesis were of commercial grade. 8-Bromoguano-
sine was purchased from Chemtronica. Unless otherwise
stated, all large-scale syntheses were performed in an
appropriately sized jacketed reactor with overhead stirring
and at room temperature, and compound purity is given as the
relative area % on HPLC. Thin-layer chromatography (TLC)
was performed on Merck pre-coated silica gel 60 F254 glass-
backed or aluminum plates and visualized by UV and/or by
charring with 8% (v/v) sulfuric acid in methanol, 8%
anisaldehyde in ethanolic sulfuric acid, or standard potassium
permanganate solution. HPLC was carried out on a Dionex
Ultimate 3000 system with UV detection at 254 nm. Reversed-
phase HPLC (RP-HPLC) was performed on a Waters XBridge
C18 XP column (50 × 3 mm) with 1 mL/min flow rate and a
linear gradient of 0−95% of buffer B in buffer A over 6 min at
40 °C. Buffers for RP-HPLC were as follows: (A) 95% 5 mM
ammonium acetate, 5% MeCN, pH 6.5 and (B) MeCN. High-
resolution mass spectra were obtained from a Waters G2-XS
-QToF instrument. All NMR spectra were recorded on a
Bruker AV 500 MHz (500.13 MHz in 1H, 125.76 MHz in 13C,
and 202.47 MHz in 31P) spectrometer using either
tetramethylsilane (TMS) or the given deuterated solvent as
an internal standard. Chemical shifts (δ scale) are reported in
parts per million (ppm), and coupling constants (J values) are
reported in Hertz (Hz).
XRPD analyses were performed at 20 °C on a PANalytical
X’Pert PRO instrument, equipped with a Cu X-ray tube and a
PIXcel detector. Automatic divergence and antiscatter slits
were used together with 0.02 rad Soller slits and a Ni filter.
Solid samples were analyzed on cut silicon zero background
holders (ZBH), while slurry samples were dripped on porous
alumina filter substrates, which produce peaks at 25.6, 35.0,
and 37.7 in 2θ. The randomness of the samples was diminished
by spinning them during the analysis. All samples were
analyzed between 2 and 40° in 2θ over 17 min. Melting points
are reported as the DSC onset. If no melting was found, the
exotherm onset or peak was given. DSC was carried out in a
Mettler DSC822e calorimeter under a nitrogen atmosphere.
The samples were weighed into a 40 μL Al cup, which were
then closed with a pierced lid. Thermogravimetric analyses
were performed on a Mettler TGA/SDTA 851e. The samples
were weighed into a 100 μL Al cup and flushed with dry
nitrogen gas during analyses. The scanning was done between
25 and 300 °C with a rate of 10 °C/min.
8-Bromo-β-phenyl-1,N2-ethenoguanosine (2). 8-Bromo-
guanosine (683 g, 1.86 mol) was vacuum-dried to reduce the
water content to under 0.5% and then dissolved in DMSO
(3.41 L, 5 vol); 2-bromoacetophenone (443 g, 1.5 equiv, 2.23
mol) was charged, followed by dropwise addition of DBU (706
g, 2.5 equiv, 4.64 mol) over 30 min to the reaction mixture,
which was kept at around 25 °C. The reaction was stirred for 1
h before addition of concn acetic acid (334 g, 3 equiv, 5.57
mol). The product was precipitated by slow addition of water
(2.7 L, 4 vol) to the reaction mixture, filtered, and washed with
water (5.5 L, 8 vol), followed by MeCN (5.5 L, 8 vol). After
drying under a vacuum at 80 °C for 5 h, the nucleoside 2 (613
g, 71.5, 98.5% HPLC purity) was recovered as a white
crystalline solid. 1H NMR (500 MHz, DMSO-d6): δ 13.09 (br
s, 1H), 8.24 (s, 1H), 7.95−7.90 (m, 2H), 7.52−7.46 (m, 2H),
7.43−7.38 (m, 1H), 5.83 (d, J = 6.1 Hz, 1H), 5.52 (d, J = 6.2
Hz, 1H), 5.23 (q, J = 5.9 Hz, 1H), 5.16 (d, J = 5.3 Hz, 1H),
4.87 (t, J = 6.1 Hz, 1H), 4.30−4.24 (m, 1H), 3.95−3.89 (m,
1H), 3.78−3.70 (m, 1H), 3.63−3.56 (m, 1H). 13C NMR (126
MHz, DMSO-d6): δ 150.7, 150.1, 145.7, 129.7, 129.0, 128.9,
127.8, 125.3, 123.1, 116.3, 103.6, 90.1, 85.7, 70.5, 70.0, 62.0.
MS (M − H) m/z: 460.0257 calcd for C18H16BrN5O5; found,
460.0259 (ES−). DSC (exotherm, peak): 248 °C (see the
Supporting Information).
8-Bromo-β-phenyl-1,N2-etheno-2′,5′-ditriisopropylsilylox-
yguanosine (3). The starting nucleoside 2 (480 g, 0.99 mol)
was suspended in DMF (2.4 L, 5 vol). Imidazole (336 g, 5
equiv, 4.93 mol) was added to the suspension, followed by
TIPS-Cl (951 g, 5 equiv, 0.54 mmol), which caused the
starting material to gradually dissolve. The mixture was stirred
overnight before quenching with water (178 mL, 10 equiv,
9.87 mol) and later diluted with toluene (7.2 L, 15 vol). The
organic phase was washed with water (3 × 2.4 L) and
evaporated. Isopropyl acetate (2.4 L, 5 vol) was added to the
resulting crude oil and stirred overnight. The solids were
filtered, washed with one cake volume (672 mL) of isopropyl
acetate, and vacuum-dried at 35 °C overnight, affording the
diprotected nucleoside 3 (462.4 g, 58.4, 99.2% HPLC purity)
as a white crystalline solid. 1H NMR (500 MHz, DMSO-d6): δ
13.09 (br s, 1H), 8.25 (d, J = 1.9 Hz, 1H), 7.96−7.87 (m, 2H),
7.53−7.47 (m, 2H), 7.44−7.39 (m, 1H), 5.90 (d, J = 4.5 Hz,
1H), 5.42 (s, 1H), 4.90 (d, J = 7.4 Hz, 1H), 4.47 (br s, 1H),
4.02−3.93 (m, 2H), 3.92−3.85 (m, 1H), 1.12−0.72 (m, 42H).
13C NMR (126 MHz, DMSO-d6): δ 149.9, 145.7, 129.6, 129.0,
129.0, 127.7, 125.3, 116.2, 103.6, 91.1 (br s), 85.0, 72.2, 69.8,
63.1, 17.8, 17.7, 17.6, 17.5, 11.6, 11.4. MS (M − H) m/z:
772.2925 calcd for C36H56BrN5O5Si2; found, 772.2950 (ES
−).
DSC (onset): 193 °C (see Supporting Information).
8-Bromo-β-phenyl-1,N2-etheno-2′-triisopropylsilyloxy-
guanosine (4). 2′,5′-Disilylated nucleoside 3 (461 g, 0.57 mol)
was dissolved in DCM (4.61 L, 10 vol). TFA (231 mL, 0.5 vol)
and water (922 mL, 2 vol) were charged into the vessel and
stirred overnight. The mixture was neutralized with 35% aq
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ammonia (0.25 vol), filtered through packed celite to remove
the overhydrolyzed byproduct, and washed with DCM (922
mL, 2 vol). The organic phases were washed with water (3 ×
100 mL) and evaporated, affording a crude solid which was
resuspended in MeCN (3.23 L, 7 vol) over three nights.
Filtering and washing the solids with MeCN (461 mL, 1 vol)
followed by vacuum drying at 35 °C overnight gave the
monoprotected nucleoside 4 (257 g, 74.2%, 99.2% HPLC
purity) as a white crystalline solid. 1H NMR (500 MHz,
DMSO-d6): δ 13.12 (s, 1H), 8.25 (s, 1H), 7.97−7.90 (m, 2H),
7.53−7.46 (m, 2H), 7.44−7.38 (m, 1H), 5.92 (d, J = 6.5 Hz,
1H), 5.45 (br s, 1H), 5.07 (d, J = 6.0 Hz, 1H), 4.92 (t, J = 6.2
Hz, 1H), 4.29−4.23 (m, 1H), 4.03−3.97 (m, 1H), 3.83−3.76
(m, 1H), 3.65−3.58 (m, 1H), 0.98−0.76 (m, 21H). 13C NMR
(126 MHz, DMSO-d6): δ 150.6, 150.0, 145.6, 129.7, 129.0,
127.6, 125.4, 116.4, 103.7, 90.0, 86.4, 71.5, 70.8, 61.9, 17.5,
17.3, 11.5. MS (M − H) m/z: 616.1591 calcd for
C27H36BrN5O5Si; found, 616.1615 (ES
−). DSC (onset): 93
°C (see the Supporting Information).
Triethylammonium 8-Bromo-β-phenyl-1,N2-etheno-2′-
triisopropylsilyloxyguanosine-5′-H-phosphonate (5). Com-
pound 4 (262 g, 0.42 mol) was dissolved in DCM (4.98 L, 19
vol), and pyridine (262 mL, 1 vol). Diphenylphosphite (292 g,
3 equiv, 1.25 mol) was charged, and after 2 h, the reaction was
quenched with water (262 mL, 1 vol) and Et3N (262 mL, 1
vol) and stirred for 1 h. The mixture was washed with water (2
× 2.5 L), and the organic phase was co-evaporated with 2-
propanol and subsequently with ethyl acetate. The crude was
recrystallized from ethyl acetate (2.62 L, 10 vol), and the solids
were filtered and washed with ethyl acetate (524 mL, 2 vol),
giving the monoester 5 (312 g, 90.0%, 96.2% HPLC purity) as
a white crystalline powder. 1H NMR (500 MHz, DMSO-d6): δ
15.02 (br s, 1H), 10.16 (br s, 1H), 8.19 (br s, 1H), 7.96−7.90
(m, 2H), 7.49−7.43 (m, 2H), 7.40−7.34 (m, 1H), 6.71 (d, JPH
= 598.7 Hz, 1H), 5.87 (d, J = 6.0 Hz, 1H), 5.52 (br s, 1H),
5.38 (t, J = 5.6 Hz, 1H), 4.46−4.41 (m, 1H), 4.29−4.19 (m,
1H), 4.16−4.11 (m, 1H), 4.06−3.97 (m, 1H), 2.95 (q, J = 7.3
Hz, 6H), 1.07 (t, J = 7.3 Hz, 9H), 1.00−0.75 (m, 21H). 13C
NMR (126 MHz, DMSO-d6): δ 150.5, 150.3, 146.1, 129.9,
129.0, 128.7, 128.1, 125.0, 122.6, 116.0, 103.0, 90.6, 85.0 (d,
JPC = 7.7 Hz, 1C), 72.7, 70.7, 63.1(d, JPC = 4.1 Hz, 1C), 45.2,
17.5, 17.4, 11.5, 8.3. 31P NMR (203 MHz, DMSO-d6): δ 3.33
(d, 1JHP = 598.4 Hz and t,
3JHP = 6.3 Hz). MS (M − Et3NH+)
m/z: 680.1305 calcd for C27H36BrN5O7PSi; found, 680.1315




guanosine-3′,5′-cyclicmonophosphorothiotic acid (6). 2,6-
Lutidine (199 g, 5 equiv, 1.86 mol) was added to a solution of
5 (310 g, 0.37 mol) in DCM (6.2 L, 20 vol), followed by
pivaloyl chloride (67 mL, 1.5 equiv, 0.56 mol). Sulfur (18 g,
1.5 equiv, 0.56 mol) and triethylamine (56 g, 1.5 equiv, 0.56
mol) were added after 45−60 min but no later to prevent
epimerization of the desired SP-cyclic H-phosphonate inter-
mediate to its RP-diastereomer. The solution was washed with
water (2 × 1.24 L), and the organic phase was evaporated. The
residues were stirred in MeCN (1.55 L, 5 vol), which
precipitated sulfur as yellow crystals that were filtered off.
Aqueous hydrobromic acid (3.1 L, 10 vol, 1 M) was added to
the resulting filtrate, precipitating a crude solid which was
filtered out and resuspended in MeCN (1.55 L, 5 vol), filtered,
and washed with one cake volume of MeCN. Removal of
solvent residues in vacuo gave the phosphorothioate 6 as a
crude white solid, which was used for the following step. 31P
NMR (203 MHz, DMSO-d6): δ 53.23 (d, JHP = 19.5 Hz)
(phosphorus splitting observed as a doublet instead of a
quartet despite three adjacent ribose protons). MS (M − H)
m/z: 694.0920 calcd for C27H35BrN5O6PSSi; found, 694.0978





thylamine trishydrofluoride (620 mL, 2 vol) was charged to
a solution of the crude phosphorothiotic acid 6 in THF (1.24
L, 4 vol). A precipitate formed over three nights, which was
filtered out and washed with THF (500 mL, 1.6 vol). Then, it
was resuspended in MeCN (930 mL, 3 vol) for 1 h before
filtering and washing with one cake volume of MeCN,
affording crystalline 1a. Cooling recrystallization of this
material from 20 volumes of 99% EtOH, followed by filtration
and washing with one cake volume of the same, affords the
target cGMPS 1a (126.5 g, 49.5%, two steps) as a white
crystalline powder with >99.9% HPLC purity. 1H NMR (500
MHz, DMSO-d6): δ 13.58 (br s, 1H), 9.41 (br s, 1H), 8.23 (s,
1H), 7.95−7.90 (m, 2H), 7.50−7.44 (m, 2H), 7.42−7.36 (m,
1H), 5.89 (d, J = 4.9 Hz, 1H), 5.73 (d, J = 1.6 Hz, 1H), 5.03 (t,
J = 5.2 Hz, 1H), 4.97−4.89 (m, 1H), 4.20−4.07 (m, 2H),
4.06−3.98 (m, 1H), 3.09 (q, J = 7.3 Hz, 6H), 1.17 (t, J = 7.3
Hz, 9H). 13C NMR (126 MHz, DMSO-d6): δ 150.4, 150.0,
145.9, 129.7, 129.0, 128.9, 127.8, 125.2, 122.7, 116.1, 103.6,
93.4, 75.3 (d, JPC = 6.4 Hz, 1C), 71.5 (d, JPC = 5.3 Hz, 1C),
69.6 (d, JPC = 7.2 Hz, 1C), 65.6 (d, JPC = 9.1 Hz, 1C), 45.7,
8.6. 31P NMR (203 MHz, DMSO-d6): δ 53.14 (d,
3JHP = 19.7
Hz) (phosphorus splitting observed as a doublet instead of a
quartet despite three adjacent ribose protons). MS (M −
Et3NH
+) m/z: 537.9586 calcd for C18H14BrN5O6PS; found,




The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.oprd.1c00230.
Spectral data (HPLC, 1H NMR, 13C NMR, 31P NMR,
1H-decoupled 31P NMR, XRPD, DSC, and TGA) for the
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